1. Yang YS, Han BD, Han K, Jung JH, Son JW, Taskforce Team of the Obesity Fact Sheet of the Korean Society for the Study of Obesity. Obesity Fact Sheet in Korea, 2021: trends in obesity prevalence and obesity-related comorbidity incidence stratified by age from 2009 to 2019. J Obes Metab Syndr 2022;31:169–177.

3. Baek HS, Park JY, Yu J, et al. Characteristics of glycemic control and long-term complications in patients with young-onset type 2 diabetes. Endocrinol Metab (Seoul) 2022;37:641–651.

4. Korean Society for the Study of Obesity. 2022 Obesity fact sheet. Seoul: Korean Society for the Study of Obesity, 2022. 5. Park J, Ahmadi SF, Streja E, et al. Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis 2014;56:415–425.

6. Ni YN, Luo J, Yu H, et al. Can body mass index predict clinical outcomes for patients with acute lung injury/acute respiratory distress syndrome? A meta-analysis. Crit Care 2017;21:36.

7. Park J, Lee SH, Lee JH, et al. Association between high preoperative body mass index and mortality after cancer surgery. PLoS One 2022;17:e0270460.

8. D'Souza A, Lee S, Zhu X, Pasquini M. Current use and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant 2017;23:1417–1421.

10. Fuji S, Takano K, Mori T, et al. Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT. Bone Marrow Transplant 2014;49:1505–1512.

11. Aoyama T, Notsu A, Ichimaru K, et al. Impact of body mass index on 5-year survival rates in patients undergoing allogeneic hematopoietic stem cell transplantation. Nutr Metab Insights 2022;15:11786388221128362.

12. Ren G, Cai W, Wang L, et al. Impact of body mass index at different transplantation stages on postoperative outcomes in patients with hematological malignancies: a meta-analysis. Bone Marrow Transplant 2018;53:708–721.

13. Jaime-Pérez JC, Colunga-Pedraza PR, Gutiérrez-Gurrola B, et al. Obesity is associated with higher overall survival in patients undergoing an outpatient reduced-intensity conditioning hematopoietic stem cell transplant. Blood Cells Mol Dis 2013;51:61–65.

14. Yu J, Lin S, Luo Y, et al. Obesity is correlated with poor outcome after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia. Jpn J Clin Oncol 2020;50:889–896.

15. Korean Society for the Study of Obesity. Clinical practice guidelines for obesity. Seoul: Korean Society for the Study of Obesity, 2022;8th. 16. Baek JH, Park YM, Han KD, Moon MK, Choi JH, Ko SH. Comparison of operational definition of type 2 diabetes mellitus based on data from Korean National Health Insurance Service and Korea National Health and Nutrition Examination Survey. Diabetes Metab J 2023;47:201–210.

17. Mas-Peiro S, Papadopoulos N, Walther T, Zeiher AM, Fichtlscherer S, Vasa-Nicotera M. Nutritional risk index is a better predictor of early mortality than conventional nutritional markers after transcatheter aortic valve replacement: a prospective cohort study. Cardiol J 2021;28:312–320.

18. Chen L, Qi Y, Kong X, et al. Nutritional risk index predicts survival in patients with breast cancer treated with neoadjuvant chemotherapy. Front Nutr 2022;8:786742.

19. Tentolouris A, Ntanasis-Stathopoulos I, Terpos E. Obesity and multiple myeloma: emerging mechanisms and perspectives. Semin Cancer Biol 2023;92:45–60.

20. Foran JM, Sun Z, Lai C, et al. Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: an ECOG-ACRIN analysis. Cancer 2023;129:2479–2490.

21. Bilgihan MT, Ciftciler R. The effect of obesity and body mass index on hematologic malignancies. Metab Syndr Relat Disord 2023;21:353–361.

22. Castillo JJ, Reagan JL, Ingham RR, et al. Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. Leuk Res 2012;36:868–875.

23. Simati S, Kokkinos A, Dalamaga M, Argyrakopoulou G. Obesity paradox: fact or fiction? Curr Obes Rep 2023;12:75–85.

24. Brunner AM, Sadrzadeh H, Feng Y, et al. Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol 2013;88:642–646.

25. Egnell C, Hallböök H, Heyman M, et al. Impact of body mass index on outcome and treatment-related toxicity in young adults with acute lymphoblastic leukemia. Acta Oncol 2023;62:1723–1731.

26. Sucak GT, Suyanı E, Baysal NA, et al. The role of body mass index and other body composition parameters in early post-transplant complications in patients undergoing allogeneic stem cell transplantation with busulfan-cyclophosphamide conditioning. Int J Hematol 2012;95:95–101.

27. Robins HI, Eickhoff J, Gilbert MR, et al. The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. Neurooncol Pract 2019;6:473–478.

28. Zhang N, Wu J, Wang Q, et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J 2023;13:82.

29. Wei H, Kuang P, Liu T. Comparative study on allogeneic with autologous hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the era of TKIs: a systematic review and meta-analysis. Ann Hematol 2020;99:2619–2628.

30. Murry DJ, Riva L, Poplack DG. Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl 1998;11:48–51.

31. Lu Y, Ma X, Pan J, Ma R, Jiang Y. Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation. Lipids Health Dis 2022;21:65.

32. Griffith ML, Jagasia M, Jagasia SM. Diabetes mellitus after hematopoietic stem cell transplantation. Endocr Pract 2010;16:699–706.

33. Engelhardt BG, Savani U, Jung DK, et al. New-onset post-transplant diabetes mellitus after allogeneic hematopoietic cell transplant is initiated by insulin resistance, not immunosuppressive medications. Biol Blood Marrow Transplant 2019;25:1225–1231.

34. Lee SH, Park SY, Choi CS. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J 2022;46:15–37.

35. Premstaller M, Perren M, Koçack K, et al. Dyslipidemia and lipid-lowering treatment in a hematopoietic stem cell transplant cohort: 25 years of follow-up data. J Clin Lipidol 2018;12:464–480.e3.

36. Mohammadi M, Vaezi M, Mirrahimi B, Hadjibabaie M. Clinical use of statins in hematopoietic stem cell transplantation: old drugs and new horizons. Int J Hematol Oncol Stem Cell Res 2016;10:42–50.

37. Francula-Zaninovic S, Nola IA. Management of measurable variable cardiovascular disease’ risk factors. Curr Cardiol Rev 2018;14:153–163.

38. Hamadani M, Gibson LF, Remick SC, et al. Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. J Clin Oncol 2013;31:4416–4423.

39. Ando T, Fujisawa S, Teshigawara H, et al.; Yokohama Cooperative Study Group for Hematology (YACHT). Impact of treatment-related weight changes from diagnosis to hematopoietic stem-cell transplantation on clinical outcome of acute myeloid leukemia. Int J Hematol 2019;109:673–683.